The UK based CDMO, eXmoor pharma, has gained a license from the UK MHRA authorizing the manufacture of good manufacturing practice (GMP)-grade cell and gene therapy materials for use in clinical trials.

The approval marks the end of a two-year project to construct a 65 thousand square foot advanced therapies manufacturing facility. The company’s Cell & Gene Therapy Centre manufacturing hub has integrated process development and analytical labs, four GMP clean rooms and fill/finish capability and can support scale-up, optimization and manufacture of cell therapies, RNA therapies and viral vectors. The centre has up to 2 x 200L bioreactors and multiple autologous cell therapy stations per suite.